Kazia Therapeutics Ltd ADR (KZIA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $75.65M
Last updated: Nov 17, 2026 at 11:04 AM ET
Kazia Therapeutics Ltd ADR (KZIA) Financials: Revenue, Profit and Cash Flow
Kazia Therapeutics Ltd ADR reported revenue of AUD 42.00K for the fiscal year ended Jun 30, 2025, down 98.2% from the year before. That year, net income was AUD -20.70M with a net margin of -49290.5%, operating cash flow was AUD -13.28M and free cash flow was AUD -13.28M. The quarter ended Dec 31, 2025 had net income of AUD -12.32M.
Revenue and Margins
Over the 9 years to Jun 2025, revenue fell from AUD 4.07M, a compound annual decline of 39.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Jun 2025 | 42.00K | -98.2% | 100.0% | -33850.0% | -49290.5% |
| Jun 2024 | 2.31M | +415755.9% | 100.0% | -1233.2% | -1160.2% |
| Jun 2023 | 555 | -94.5% | 100.0% | -4346661.1% | -3687419.8% |
| Jun 2022 | 10.00K | -99.9% | 100.0% | -253990.0% | -250140.0% |
| Jun 2021 | 15.18M | +1436.6% | 100.0% | -42.0% | -55.5% |
| Jun 2020 | 988.11K | +63038.0% | 100.0% | -1234.3% | -1261.7% |
| Jun 2019 | 1.56K | -88.1% | 100.0% | -535463.3% | -656230.0% |
| Jun 2018 | 13.11K | -99.9% | 100.0% | -95262.4% | -46071.1% |
| Jun 2017 | 8.79M | +115.9% | 100.0% | -123.5% | -121.4% |
| Jun 2016 | 4.07M | N/A | 100.0% | -313.7% | -296.3% |
Income Statement
In the fiscal year ended Jun 2025, the net loss narrowed from the year before. In the quarter ended Dec 2025, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 42.00K | 2.31M | 555 | 10.00K | 15.18M | 988.11K | 1.56K | 13.11K | 8.79M | 4.07M |
| Gross profit | 42.00K | 2.31M | 555 | 10.00K | 15.18M | 988.11K | 1.56K | 13.11K | 8.79M | 4.07M |
| Research and development | 7.33M | 17.38M | 15.56M | 20.17M | 14.54M | 9.49M | 6.48M | 9.77M | 11.14M | 9.89M |
| Operating income | -14.22M | -28.46M | -24.12M | -25.40M | -6.38M | -12.20M | -8.38M | -12.49M | -10.85M | -12.77M |
| Net income | -20.70M | -26.78M | -20.47M | -25.01M | -8.42M | -12.47M | -10.27M | -6.04M | -10.67M | -12.06M |
| EBITDA | -13.28M | -26.59M | -22.28M | -23.52M | -5.11M | -11.11M | -7.71M | N/A | -9.44M | -11.72M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | 19.71K | 19.71K | 22.29K | 2.48M | 2.48M | 5 | 1.00K | N/A | 278 | N/A | N/A |
| Gross profit | N/A | 19.71K | 19.71K | 22.29K | 2.48M | 2.48M | 5 | 1.00K | N/A | 278 | -626.20K | -671.83K |
| Operating income | -13.30M | -4.85M | -4.85M | -9.37M | -19.58M | -19.58M | -8.88M | -10.51M | N/A | -5.26M | -13.64M | -25.38M |
| Net income | -12.32M | -9.95M | -9.95M | -10.45M | -17.95M | -17.95M | -8.82M | -6.88M | N/A | -3.44M | -13.59M | -11.81M |
Balance Sheet
As of Jun 2025, cash and equivalents exceeded short-term debt of AUD 396.00K by 3.95M. Shareholder equity was negative, at -8.30M, as total liabilities of 14.36M exceeded total assets of 6.06M.
Annual
| Line item | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 6.06M | 21.59M | 28.08M | 35.89M | 58.09M | 23.06M | 21.18M | 28.18M | 35.91M | 35.52M |
| Current assets | 4.93M | 6.14M | 10.77M | 9.45M | 29.39M | 10.65M | 7.54M | 9.26M | 19.48M | 34.09M |
| Cash and equivalents | 4.34M | 1.66M | 5.24M | 7.36M | 27.59M | 8.76M | 5.43M | 5.96M | 14.45M | 33.45M |
| Total liabilities | 14.36M | 31.60M | 16.03M | 17.61M | 20.24M | 8.94M | 7.01M | 8.93M | 10.57M | 1.59M |
| Short-term debt | 396.00K | 634.00K | 1.80M | 1.84M | N/A | N/A | 0 | 84.00K | 10.00K | 10.00K |
| Shareholder equity | -8.30M | -10.02M | 12.05M | 18.27M | 37.85M | 14.13M | 14.20M | 19.24M | 25.34M | 33.93M |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 71.04M | 6.06M | 6.06M | 17.91M | 21.59M | 21.59M | 24.38M | 28.08M | 28.09M | N/A | 27.84M | 35.89M |
| Total liabilities | 24.62M | 14.36M | 14.36M | 21.72M | 31.60M | 31.60M | 19.12M | 16.03M | 16.03M | N/A | 16.25M | 17.61M |
| Cash and equivalents | 69.39M | 4.34M | 4.34M | 3.06M | 1.66M | 1.66M | 3.56M | 5.24M | 5.24M | N/A | 4.39M | 7.36M |
| Shareholder equity | 46.42M | -8.30M | -8.30M | -3.81M | -10.02M | -10.02M | 5.27M | 12.05M | 12.05M | N/A | 11.58M | 18.27M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Jun 2025.
Annual
| Line item | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M | -8.81M | -6.71M | -8.66M | -11.43M | -11.98M |
| Capital expenditures | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11.65K | 525.00K |
| Free cash flow | -13.28M | -9.58M | -15.16M | -22.76M | -9.11M | -8.81M | -6.71M | -8.66M | -11.45M | -12.51M |
| Investing cash flow | N/A | N/A | N/A | -2.37M | -2.36M | -2.36M | 2.36M | 150.00K | -7.12M | -522.00K |
| Financing cash flow | 15.98M | 5.99M | 12.97M | 3.73M | 28.11M | 12.14M | 3.82M | 3.82M | -17.66K | 782.00K |
Quarterly
| Line item | Dec 2025 | Sep 2025 | Jun 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.07M | -4.14M | -4.14M | -4.21M | -3.25M | -3.25M | -6.33M | -6.35M | -3.18M | -3.18M | -8.81M |
| Capital expenditures | N/A | 4.14M | 4.14M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | N/A | -8.28M | -8.28M | -4.21M | -3.25M | -3.25M | -6.33M | -6.35M | -3.18M | -3.18M | -8.81M |
Frequently Asked Questions About KZIA
What is Kazia Therapeutics Ltd ADR's annual revenue?
Kazia Therapeutics Ltd ADR reported revenue of AUD 42.00K for the fiscal year ended Jun 30, 2025.
How fast is Kazia Therapeutics Ltd ADR's revenue growing?
Revenue was down 98.2% for the fiscal year ended Jun 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 61.3%.
Is Kazia Therapeutics Ltd ADR profitable?
No. Kazia Therapeutics Ltd ADR reported net income of AUD -20.70M for the fiscal year ended Jun 30, 2025, with a net margin of -49290.5%.
How much free cash flow does KZIA generate?
For the fiscal year ended Jun 30, 2025, operating cash flow of AUD -13.28M minus capital expenditures of AUD 0 produced free cash flow of AUD -13.28M.
How much debt does Kazia Therapeutics Ltd ADR have?
The balance sheet dated Jun 30, 2025 reported short-term debt of AUD 396.00K and cash and equivalents of AUD 4.34M.
KZIA pages: Overview, Financials